Key Takeaways Lilly's Mounjaro and Zepbound drive half its revenues, fueling over 30% expected 2025 sales growth.AbbVie rebounds post-Humira LOE with Skyrizi and Rinvoq, targeting $25B in combined 2025 sales.2025 estimates for Lilly indicate 37% sales and 76.7% EPS growth, outpacing AbbVie's 7.6% and 18.9%.Eli Lilly (LLY) and AbbVie (ABBV) are large, well-established U.S. pharmaceutical companies, boasting several blockbuster drugs, robust R&D pipelines, strong market capitalization and global footprint. Bo ...

2026 could be a pivotal year for Zura Bio Ltd. (ZURA), with key data readouts for its lead investigational drug expected to significantly influence the company's strategic direction and market position.Zura is a clinical-stage, multi-asset immunology company advancing treatments for immune-mediated diseases where there is an unmet medical need. Its lead product candidate is Tibulizumab, a potential first-in-class dual-pathway biologic designed to target cytokines IL-17A and BAFF. Tibulizumab is currently b ...

With many stocks looking overvalued, many investors may be tempted to sell. However, there are several factors to consider before taking profits: Time horizon – when an investor will need the money The availability of better alternative investments Tax ramifications from taking short-term or long-term gains This article only focuses on the first factor. For long-term investors, time is almost always an ally. But that depends on the stock. Blue-chip stocks come to mind. The companies behind these stocks ar ...

(Reuters) -Drugmaker AbbVie said on Friday it has lowered its annual profit forecast, after a flagging an expected $2.7 billion charge related to in-process research and development (IPR&D) expenses in the third quarter. Shares of the North Chicago-based company were down nearly 1% at $232.0 in extended trade. AbbVie said in a regulatory filing that such expenses may arise from collaborations, licensing deals or asset buys, but are not forecast due to uncertainty around timing and occurrence. It did not ...

AbbVie Inc. (NYSE:ABBV) ranks among the stocks with low beta that can beat market volatility. On September 24, Leerink Partners maintained its Outperform rating on AbbVie Inc. (NYSE:ABBV) and raised its price target on the company’s shares from $210 to $243. The increase comes after AbbVie Inc. (NYSE:ABBV) announced on September 11 that it had reached a settlement that would allow generic Rinvoq to be introduced in April 2037, over four years later than Leerink had previously predicted. Pixabay/Public Do ...

AbbVie (ABBV) stands out after its Allergan acquisition thanks to a transformed portfolio and higher long-term growth prospects. ABBV is trading at fresh all-time highs. Shares have a 100% Barchart “Buy” opinion and are trading above key moving averages. Analyst and investor sentiment is positive, with most major firms rating ABBV a “Buy” or “Strong Buy” and price targets suggesting further upside. Today’s Featured Stock Valued at $394 billion, AbbVie (ABBV) has become one of the top-most phar ...

Core Insights - Alvotech (ALVO) is rapidly expanding in the biosimilar/generic market through a partnership-driven model, focusing on development and manufacturing while partners manage marketing and sales [1] - The company's immunology biosimilars, particularly Simlandi and Selarsdi, have driven early momentum, with product revenues increasing over 200% year over year to nearly $205 million in the first half of 2025 [2][5] - Alvotech is diversifying its portfolio by entering ophthalmology with the EU approval of Mynzepli, a biosimilar to Regeneron's Eylea, and expanding partnerships to develop biosimilars in neurology and oncology [3][4][5] Company Strategy - Alvotech's alliance-driven model allows it to mitigate risks associated with biosimilar launches and accelerate market entry for multiple products simultaneously [1] - By leveraging established partners like Teva Pharmaceuticals and Stada, Alvotech has efficiently scaled adoption of its products without the financial burden of extensive sales infrastructure [2] - The company is strategically expanding its partnerships with Dr. Reddy's Laboratories and Advanz Pharma to develop biosimilars for key therapeutic areas, including oncology and neurology [4]

Group 1 - Companies that consistently raise dividends have outperformed the S&P 500 by 2.5 percentage points annually since 1972, with a $10,000 investment in dividend growers in 1972 now worth over $4 million compared to $1.6 million in the S&P 500 [2] - Five blue-chip companies exemplify the strategy of combining current income with dividend growth, contributing to wealth accumulation [3] Group 2 - AbbVie (NYSE: ABBV) has a dividend yield of 2.97% and has raised its dividend for 12 consecutive years, despite facing a significant patent cliff with Humira, with a payout ratio of 303% that is distorted by acquisition accounting [4][5] - Costco (NASDAQ: COST) has a low yield of 0.57% but boasts a 13.2% annual dividend growth rate over the past five years, with a conservative payout ratio of 27%, and its membership fees could cover the entire dividend [6][7] - American Express (NYSE: AXP) offers a 0.92% yield but has compounded its dividend at 12% annually over the past five years, with only 21.3% of earnings allocated to dividends, controlling both card issuance and payment processing [10] Group 3 - The combined shareholder returns of these five companies exceed $500 billion over the past decade, with dividend growth every year, and yields ranging from 0.57% at Costco to 7.2% at Pfizer, catering to both income and growth-focused investors [9]

Core Insights - Investors are taking a bearish stance on AbbVie, with significant options activity indicating potential insider knowledge of upcoming events [1][2] - The overall sentiment among large investors is slightly bearish, with 54% bearish and 45% bullish positions [2] - Significant investors are targeting a price range of $160.0 to $220.0 for AbbVie over the past three months [3] Options Activity - In the last 30 days, 11 uncommon options trades were identified for AbbVie, with 9 puts totaling $807,896 and 2 calls totaling $67,330 [2][4] - Detailed analysis of options activity shows a focus on bearish trades, with notable put options indicating a lack of confidence in the stock's near-term performance [9] Company Overview - AbbVie is a pharmaceutical company with strong exposure to immunology and oncology, having expanded its portfolio through acquisitions, including Allergan in 2020 and recent acquisitions in neuroscience and oncology [10] - Analysts have provided a range of target prices for AbbVie, with an average target of $247.4, and individual targets ranging from $222 to $270 [12][13] Market Performance - AbbVie’s current trading volume stands at 2,435,721, with the stock price at $220.44, reflecting a 0.87% increase [15] - The stock may be approaching overbought conditions, with an earnings announcement expected in 33 days [15]

Key Takeaways AbbVie projects revenue growth in 2025 despite Humira sales falling by over 54% in the first half of 2025.Skyrizi and Rinvoq are fueling gains with new launches, head-to-head data and expanding indications.AbbVie is also expanding in oncology and neuroscience, adding new drugs and boosting migraine uptake.AbbVie (ABBV) expects to return to robust revenue growth in 2025, despite the U.S. loss of exclusivity (LOE) for its flagship drug Humira over two years ago. The drug, which went off-patent i ...